Theme

Extending Life Beyond 5 Years: The 12.5-Month Survival Advantage

Source
Source: Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386:942-50. MONALEESA-2 ClinicalTrials.gov number, NCT01958021.

First-Line Ribociclib + Letrozole vs. Placebo | N=668 Postmenopausal Patients | Median Follow-up: 80 Months

Median Overall Survival
63.9
Months
vs 51.4 Months (Placebo)
Net Survival Gain
+12.5
Months Extended Life
Surpassing 5-Year Milestone
Time to Chemotherapy
50.6
Months
Delayed by ~1 Year vs Placebo

Long-Term Survival Probability (72 Months)

At the 6-year mark, 44.2% of Ribociclib patients remain alive vs 32.0% in control.

Median Outcomes Comparison

Ribociclib consistently outperforms Placebo in both Overall Survival and Time to Chemotherapy.

Clinical Recommendation

Implement Ribociclib + Letrozole as the standard first-line protocol. This regimen significantly alters the disease timeline, offering the demonstrated ability to push median survival beyond the 5-year threshold and delay the transition to chemotherapy by approximately 12 months.

AbbreviationsQuick
CDK4/6, cyclin-dependent kinases 4 and 6; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NE, could not be estimated; PgR, progesterone receptor.
Bibliography8
  1. Başaran GA, Twelves C, Diéras V, Cortés J, Awada A. Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treat Rev 2018; 63:144-55.
  2. Lobbezoo DJA, van Kampen RJW, Voogd AC, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat 2013;141:507-14.
  3. O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol 2016; 13:417-30.
  4. Hosford SR, Miller TW. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med 2014; 7:203-15.
  5. Thangavel C, Dean JL, Ertel A, et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer 2011;18:333-45.
  6. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-83.
  7. Miller TW, Balko JM, Fox EM, et al. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 2011;1:338-51.
  8. Chen P, Lee NV, Hu W, et al. Spectrum and degree of CDK drug interactions predict clinical performance. Mol Cancer Ther 2016;15:2273-81.